Welcome to our dedicated page for Lakefront Biotherapeutics NV SEC filings (Ticker: LKFT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Lakefront Biotherapeutics NV's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Lakefront Biotherapeutics NV's regulatory disclosures and financial reporting.
Lakefront Biotherapeutics NV (LKFT) reported recent activity under its ordinary share repurchase program announced on June 9, 2026. Between August 24 and August 28, 2026, the company repurchased 127,796 shares through a discretionary mandate to an independent financial intermediary across several European trading venues.
The average price paid was €25.19 per share, for an aggregate consideration of €3,218,710.15, with individual trades executed between €24.36 and €25.66 per share. As of market close on August 28, 2026, Lakefront held 1,161,324 of its own ordinary shares.
Lakefront Biotherapeutics NV (LKFT) reports progress on its ordinary share repurchase program announced on June 9, 2026. Between August 17 and August 21, 2026, the company repurchased 117,471 shares of its own stock through an independent financial intermediary, at an average price of €24.40 per share for a total of €2,866,035.10.
Across multiple European trading venues, the prices paid ranged from a lowest price of €23.66 to a highest price of €25.70. As of market close on August 21, 2026, Lakefront holds 1,033,528 of its own ordinary shares. The company describes itself as a biotechnology business with a clinical-stage immunology and inflammation portfolio and a strong capital position, and notes that further repurchases are subject to the risks outlined in its SEC filings.
Lakefront Biotherapeutics NV (LKFT) reported that the U.S. FDA granted Orphan Drug Designation to its investigational antibody gamgertamig for treatment of pemphigus, adding to existing Fast Track and Orphan Drug designations in autoimmune hemolytic anemia and immune thrombocytopenia. Gamgertamig is being co-developed with Gilead Sciences.
Gamgertamig, an investigational BCMAxCD3 bispecific T cell engager for autoantibody‑driven immune diseases, is in Phase 2 studies, with entry into registrational studies expected in 2027. Ongoing Phase 1b trials in autoimmune cytopenias and seropositive autoimmune diseases are enrolling across multiple countries, and proof‑of‑concept basket studies in additional autoimmune indications are expected.
Lakefront Biotherapeutics NV (LKFT) reported that Bank of America Corporation has crossed a major shareholding threshold under Belgian transparency rules. On August 18, 2026, Bank of America and its affiliates exceeded the 10% voting rights threshold in Lakefront through a combination of shares and derivative instruments.
As of August 19, 2026, Bank of America and its affiliates held 1,419,144 voting rights and 5,243,453 equivalent financial instruments, representing together 10.11% of Lakefront’s voting rights, based on a denominator of 65,897,071 outstanding shares. The position includes physical-settled rights of use/recall and various cash-settled swap positions across several Bank of America entities.
Lakefront Biotherapeutics NV (LKFT) reports progress under its share repurchase program announced on June 9, 2026. Between August 10 and 14, 2026, the company bought back 107,871 ordinary shares through a discretionary mandate to an independent financial intermediary across multiple European trading venues.
The shares were repurchased at an average price of €24.14, for an aggregate cost of €2,604,002.56, with prices ranging from €22.88 to €24.98. As of market close on August 14, 2026, Lakefront held 916,057 of its own ordinary shares. The company describes itself as a biotechnology business with a clinical-stage portfolio in immunology and inflammation, including gamgertamig, a BCMAxCD3 T-cell engager for autoimmune diseases, and notes that its plans to continue repurchasing shares are subject to the usual forward-looking risks and uncertainties.
Lakefront Biotherapeutics reported progress under its share repurchase program announced on June 9, 2026. Between August 3 and August 7, 2026, the company repurchased 103,970 ordinary shares through an independent financial intermediary at an average price of €23.18 per share, for a total consideration of €2,409,901.40. During this period, prices ranged from a low of €22.32 to a high of €23.86. As of market close on August 7, 2026, Lakefront held 808,186 of its own ordinary shares.
Lakefront Biotherapeutics reported unaudited first half-year 2026 results, highlighting the completed acquisition of Ouro Medicines with Gilead Sciences to advance its lead T‑cell engager, gamgertamig, in autoimmune diseases. Management plans additional proof‑of‑concept basket studies for gamgertamig in 2027 and reported encouraging durability and consistent clinical responses from ongoing trials.
Financially, total net revenues were €18.6 million for the six months ended June 30, 2026, down from €140.3 million a year earlier. Operating loss from continuing operations narrowed to €107.2 million from €215.7 million, as prior‑year results included €131.6 million of reorganization charges. Net financial income of €123.2 million drove a swing to a net profit of €16.6 million, compared to a net loss of €259.1 million in the first half of 2025.
Financial investments, cash and cash equivalents totaled €2,239.5 million on June 30, 2026, versus €2,998.0 million on December 31, 2025, after €733.5 million cash out for the Ouro acquisition and €63.6 million operational cash burn. The company expects year‑end 2026 cash and financial investments of €1.975–2.050 billion, including a €50 million share repurchase, and forecasts at least €1.6 billion remaining after funding the portfolio to first gamgertamig approval.
Lakefront Biotherapeutics reported that under its share repurchase program announced on June 9, 2026, it bought back 97,497 ordinary shares between July 27 and July 31, 2026 through a discretionary mandate to an independent financial intermediary. The shares were repurchased at an average price of €24.48, for a total cost of €2,386,239.93, with transaction prices ranging between €23.68 and €25.04 across several European trading venues.
After these transactions, Lakefront held 704,216 of its own ordinary shares as of market close on July 31, 2026. The company characterizes its plans to repurchase additional ordinary shares as forward-looking statements that are subject to risks and uncertainties described in its reports filed with the SEC.
Lakefront Biotherapeutics reported that, under its share repurchase program announced on June 9, 2026, it bought back 95,670 ordinary shares between July 20 and July 24, 2026 via a discretionary mandate to an independent financial intermediary across multiple European trading venues.
The shares were repurchased at an average price of €25.41, for an aggregate consideration of €2,431,442.30, with individual transaction prices ranging from €24.56 to €26.40. As of market close on July 24, 2026, Lakefront held 606,719 of its own ordinary shares.
Lakefront Biotherapeutics reports that, under its share repurchase program announced on June 9, 2026, it bought back 98,648 ordinary shares between July 13 and July 17, 2026 through an independent financial intermediary. The shares were acquired on several European trading venues at an average price of €26.00, for a total consideration of €2,564,633.73 and within a price range of €25.60 to €26.56.
Following these transactions, Lakefront holds 511,049 of its own ordinary shares. The company describes itself as a biotechnology business focused on immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class BCMAxCD3 T‑cell engager for autoimmune diseases, and includes forward-looking statements regarding its ongoing share repurchase plans.